Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control.
Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, Sanchez H, Frahm N, Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen TM, Walker BD, Korber BT, Leitner T, Sanchez J, Brander C. Zuñiga R, et al. Among authors: galvan p. J Virol. 2006 Mar;80(6):3122-5. doi: 10.1128/JVI.80.6.3122-3125.2006. J Virol. 2006. PMID: 16501126 Free PMC article.
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. Among authors: galvan p. ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608304 Free PMC article.
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perelló A, González X, Jiménez B, Merino M, Palacios P, Pascual T, Alba E, Villanueva L, Chillara S, Ferrero-Cafiero JM, Galvan P, Prat A, Ciruelos E. Pernas S, et al. Among authors: galvan p. NPJ Breast Cancer. 2024 Nov 26;10(1):101. doi: 10.1038/s41523-024-00710-x. NPJ Breast Cancer. 2024. PMID: 39592624 Free PMC article.
Multistate outbreak of Salmonella Oranienburg infections linked to bulb onions imported from Mexico - United States, 2021.
Mitchell MR Jr, Kirchner M, Schneider B, McClure M, Neil KP, Madad A, Jemaneh T, Tijerina M, Nolte K, Wellman A, Neises D, Pightling A, Swinford A, Piontkowski A, Sexton R, McKenna C, Cornell J, Sandoval AL, Wang H, Bell RL, Stager C, Nava MCZ, de la Cruz JLL, Córdova LIS, Galván PR, Ortiz JA, Flowers S, Grisamore A, Gieraltowski L, Bazaco M, Viazis S. Mitchell MR Jr, et al. Among authors: galvan pr. Food Control. 2024 Jun;160:110325. doi: 10.1016/j.foodcont.2024.110325. Food Control. 2024. PMID: 39493539
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
Fullana B, Morales S, Petit A, Alay A, Verdaguer H, Climent F, Navarro-Perez V, Cejuela M, Galvan P, Gumà A, Llombart-Cussac A, Cordero D, Casanovas O, Prat A, Gil-Gil M, Pernas S. Fullana B, et al. Among authors: galvan p. Sci Rep. 2024 Oct 9;14(1):23626. doi: 10.1038/s41598-024-72152-1. Sci Rep. 2024. PMID: 39384801 Free PMC article. Clinical Trial.
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, Paré L, Villacampa G, Gion M, Schmid P, Colleoni M, Borrego MR, Galván P, Parker JS, Buckingham W, Perou CM, Villagrasa P, Guerrero JA, Sampayo-Cordero M, Mancino M, Prat A, Cortés J. Llombart-Cussac A, et al. Among authors: galvan p. Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464. Clin Cancer Res. 2024. PMID: 38995291 Free PMC article. Clinical Trial.
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Garcia-Fructuoso I, Rodríguez A, Gómez-Bravo R, Schettini F, Blasco P, Castillo O, González-Farré B, Adamo B, Vidal M, Muñoz M, Perou CM, Malumbres M, Gavilá J, Pascual T, Prat A, Brasó-Maristany F. Lorman-Carbó N, et al. Among authors: galvan p. Sci Rep. 2024 Jul 11;14(1):16030. doi: 10.1038/s41598-024-67126-2. Sci Rep. 2024. PMID: 38992220 Free PMC article.
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, Martínez-Sáez O, Cejalvo JM, Margelí M, Tolosa P, Salvador-Bofill FJ, Cruz J, González-Farré B, Sanfeliu E, Òdena A, Serra V, Pardo F, Luna Barrera AM, Arumi M, Guerra JA, Villacampa G, Sánchez-Bayona R, Ciruelos E, Espinosa-Bravo M, Izarzugaza Y, Galván P, Matito J, Pernas S, Vidal M, Santhanagopal A, Sellami D, Esker S, Fan PD, Suto F, Vivancos A, Pascual T, Prat A, Oliveira M. Brasó-Maristany F, et al. Among authors: galvan p. Nat Commun. 2024 Jul 11;15(1):5826. doi: 10.1038/s41467-024-50056-y. Nat Commun. 2024. PMID: 38992028 Free PMC article.
125 results